Detected ·
HemaCell
CN¥300M—
HemaCell completed the second closing of its Series B round, raising over RMB 100M in this tranche and bringing the total Series B to nearly RMB 300M. The biotech company is developing the world's first megakaryocyte injection and platelet therapeutics to address blood supply shortages.
- Website
- —
- —
- Amount
- ¥300 000 000 CNY
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-09 12:21:21 UTC
- Signal ID
- 26725265-1d15-4a88-941b-f33ebdfa37db
As the API returns it
{
"id": "26725265-1d15-4a88-941b-f33ebdfa37db",
"created_at": "2026-07-09T12:21:21.061285Z",
"company_name": "HemaCell",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 300000000,
"funding_currency": "CNY",
"funding_stage": null,
"message": "*HemaCell completed the second closing of its Series B round, raising over RMB 100M in this tranche and bringing the total Series B to nearly RMB 300M. The biotech company is developing the world's first megakaryocyte injection and platelet therapeutics to address blood supply shortages.*"
}